Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.

Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.